Clinical Trial UCI-16-53

Title

FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Principal Investigator

Leslie Randall

Details

Learn More

For more information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email ucstudy@uci.edu